This excerpt taken from the GSK 6-K filed Oct 6, 2009.
London (UK), October 6, 2009
- GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company (Walvax) today announced a cooperation agreement to form a long-term Joint Venture (JV) to develop and manufacture paediatric vaccines for use in China. The JV will produce vaccines for measles, mumps, and rubella (
) and potentially other paediatric vaccines. GSK will also transfer the technology to enable the JV to manufacture the vaccines locally over time.
"This JV further builds on GSK's global business model which has fostered innovative partnerships to develop and deliver vaccines all over the world" said